Brief Reports
Copyright ©The Author(s) 2005. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Oct 14, 2005; 11(38): 6009-6013
Published online Oct 14, 2005. doi: 10.3748/wjg.v11.i38.6009
Helicobacter pylori antibiotic resistance in Iran
Marjan Mohammadi, Delaram Doroud, Nazanin Mohajerani, Sadegh Massarrat
Marjan Mohammadi, Delaram Doroud, Nazanin Mohajerani, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran
Sadegh Massarrat, Gastroenterology Department, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
Author contributions: All authors contributed equally to the work.
Supported by a Research Grant From the Pasteur Institute of Iran, No. 198
Correspondence to: Marjan Mohammadi, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran. marjan@institute.pasteur.ac.ir
Telephone: +98-21-6480780 Fax: +98-21-6480780
Received: November 16, 2004
Revised: January 23, 2005
Accepted: January 26, 2005
Published online: October 14, 2005
Abstract

AIM: To examine the frequency of antibiotic resistance in Iranian Helicobacter pylori (H pylori) strains isolated from two major hospitals in Tehran.

METHODS: Examination of antibiotic resistance was performed on 120 strains by modified disc diffusion test and PCR-RFLP methods. In addition, in order to identify the possible causes of the therapeutic failure in Iran, we also determined the resistance of these strains to the most commonly used antibiotics (metronidazole, amoxicillin, and tetracycline) by modified disc diffusion test.

RESULTS: According to modified disc diffusion test, 1.6% of the studied strains were resistant to amoxicillin, 16.7% to clarithromycin, 57.5% to metronidazole, and there was no resistance to tetracycline. Of the clarithromycin resistant strains, 73.68% had the A2143G mutation in the 23S rRNA gene, 21.05% A2142C, and 5.26% A2142G. None of the sensitive strains were positive for any of the three point mutations. Of the metronidazole resistant strains, deletion in rdxA gene was studied and detected in only 6 (5%) of the antibiogram-based resistant strains. None of the metronidazole sensitive strains possessed rdxAgene deletion.

CONCLUSION: These data show that despite the fact that clarithromycin has not yet been introduced to the Iranian drug market as a generic drug, nearly 20% rate of resistance alerts toward the frequency of macrolide resistance strains, which may be due to the widespread prescription of erythromycin in Iran. rdxA gene inactivation, if present in Iranian H pylori strains, may be due to other genetic defects rather than gene deletion.

Keywords: H pylori, Clarithromycin, Metronidazole, Resistance, Iran